Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear
Business Wire•13/11/2026•08:30 ET
0
Key Highlights
- ➤Tandem Mobi receives FDA clearance as tubeless AID system with up to 7 days of wear
- ➤New tubeless cartridge and infusion set preserve Control-IQ+ automated insulin delivery benefits
- ➤Tandem Mobi now offers both tubeless and tubed insulin infusion options
- ➤Commercial launch of Tandem Mobi Tubeless planned for first half of 2027 in the United States
- ➤Pharmacy coverage currently reaches approximately 50% of insured U.S. lives
Expert Statements
John Sheridan, President and Chief Executive Officer of Tandem Diabetes Care
“The Tandem Mobi insulin pump was originally designed to make different wear options possible, which now includes a tubeless option with up to 7 days of wear(1)”
John Sheridan, President and Chief Executive Officer of Tandem Diabetes Care
“This clearance of the Tandem Mobi tubeless cartridge and infusion set creates even more possibilities for people living with diabetes, expanding the number of ways to experience the proven benefits of our Control-IQ+ AID technology.”
Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear
* World’s first and only tubeless automated insulin delivery (AID) system with up to 7 days of wear(1)
Get started
Create a free account to read the full story.